Effect of dexamethasone in two different doses on specific biochemical markers in patients with COVID-19
Journal of Emergency Medicine, Trauma and Acute Care
; 2022(3), 2022.
Article
in English
| EMBASE | ID: covidwho-1969686
ABSTRACT
Background:
Severe acute respiratory syndrome coronavirus 2 is the causative agent of coronavirus disease 2019 (COVID-19). The release of alarmins results in a “cytokine storm,” which can be attenuated by the immunomodulatory and anti-inflammatory effects of dexamethasone.Aim:
To evaluate and assess the effect of dexamethasone in two different doses, on D-dimer, serum ferritin, C-reactive protein (CRP) levels, and granulocyte/lymphocyte (%) in patients with COVID-19. Patients andmethods:
A total of 100 patients were randomly divided into two groups;group A patients received a higher dose of dexamethasone than those in group B. Measurements of certain hematological and biochemical markers, including D-dimer, serum ferritin, CRP, and granulocyte/lymphocyte ratio were done for all the patients in both groups. These indices were compared at different times of treatment between the two groups.Results:
The D-dimer and granulocyte/lymphocyte ratio measurements were statistically non-significant in both the groups in all three readings. The serum ferritin measurement was significant only on the 6th day of treatment. The results demonstrated that group A patients had significantly lower CRP levels on both the 3rd and 6th days of treatment.Conclusion:
Administration of a slightly higher dose of dexamethasone (8 mg per day for three days, then 6 mg per day for another 3 days) in patients hospitalized with COVID-19 effectively reduces the inflammatory and hematological biomarkers in patients who required supplemental oxygen therapy.
adult; article; clinical trial; controlled study; coronavirus disease 2019; drug megadose; drug therapy; female; ferritin blood level; granulocyte; human; human cell; human tissue; lymphocyte; major clinical study; male; nonhuman; oxygen therapy; randomized controlled trial; Severe acute respiratory syndrome coronavirus 2; biochemical marker; biological marker; C reactive protein; D dimer; dexamethasone; endogenous compound
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Experimental Studies
Topics:
Vaccines
Language:
English
Journal:
Journal of Emergency Medicine, Trauma and Acute Care
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS